Period:
Draw Mode:
| Volume | 22,489 |
|
|||||
| News | - | ||||||
| Day High | 4.28 | Low High |
|||||
| Day Low | 4.0113 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Harpoon Therapeutics Inc | HARP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.13 | -3.12% | 4.03 | 00:00:07 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.18 | 4.0113 | 4.28 | 4.03 | 4.16 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 254 | 22,489 | $ 4.16 | $ 93,541 | - | 3.8601 - 33.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:42:01 | 1 | $ 3.85 | USD |
Harpoon Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.62M | 3.88M | - | 31.92M | -67.73M | -17.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Harpoon Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HARP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.00 | 4.68 | 3.8601 | 4.12 | 32,496 | 0.03 | 0.75% |
| 1 Month | 10.70 | 10.70 | 3.8601 | 6.98 | 92,392 | -6.67 | -62.34% |
| 3 Months | 7.60 | 11.20 | 3.8601 | 8.40 | 183,100 | -3.57 | -46.97% |
| 6 Months | 6.70 | 11.20 | 3.8601 | 7.64 | 191,769 | -2.67 | -39.85% |
| 1 Year | 9.40 | 33.50 | 3.8601 | 11.52 | 707,515 | -5.37 | -57.13% |
| 3 Years | 160.10 | 252.35 | 3.8601 | 51.84 | 428,944 | -156.07 | -97.48% |
| 5 Years | 138.80 | 252.35 | 3.8601 | 65.70 | 320,632 | -134.77 | -97.1% |
Harpoon Therapeutics Description
| Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others. |